MarketVIEW: Group B Streptococcus vaccinesVacZine AnalyticsSeptember 1, 2009 25 Pages - SKU: VZAN2474453 |
| Group B beta streptococci (GBS) or Streptococcus agalactiae is an encapsulated Gram-positive coccus capable of producing a range of diseases in humans of all age ranges. In the neonate, the bacterium can cause severe life threatening sepsis and meningitis (early and late onset disease) due to ascending spread of GBS from the birth canal of colonized females (~30% of total) who are typically asymptomatic. In the 1970s GBS was the leading infectious cause of neonatal morbidity in the US with estimated 7,500-8000 cases occurring annually. Presently, GBS is still estimated to cause disease (EOD+LOD) in approximately 0.5/1000 US births although the widespread implementation of screening and intrapartum antibiotic prophylaxis (IAP) has reduced disease burden dramatically. GBS can also cause life threatening invasive disease in the immunocompromised non-pregnant adult with approximately 4.1 to 7.2 cases per 100,000 population (CDC Figures). Recent studies indicate that the rate of adult disease may be increasing.
A number of manufacturers are considering the development of a GBS prophylatic vaccine. Such a vaccine may be offered to adolescents to prevent neonatal disease after pregnancy later in life or for older women planning a pregnancy. Other possible uses might be in immunocompromised/elderly individuals who are hospitalized and reside in long-term care facilities. Please note: this is delivered as a Zip file. |
Related Markets
Vaccines Reports
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Lung Cancer, Cancer Vaccines and Protein Kinase Inhibitors
